StockData

bioAffinity Technologies vs OneMedNet

BIAF and ONMD side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIAF and ONMD compare

OneMedNet is the larger company, worth 19 times as much as bioAffinity Technologies ($293M against $15.6M).

OneMedNet grew revenue faster over the last twelve months (217% versus −23.2% for bioAffinity Technologies).

bioAffinity Technologies keeps more of each dollar of sales as profit, with a net margin of −257% compared with −584% at OneMedNet.

bioAffinity Technologies scores higher on the StockData Score (5 against 3 for OneMedNet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIAFONMD
Size and price
Market cap$15.6M$293M
Share price$1.93$4.95
Change, 1 year−93.0%−64.6%
Change, 5 years–−95.1%
Beta (5Y)–0.83
Employees5723
StockData Score
Total score5 (better)3
Valuation score3 (better)0
Growth score02 (better)
Performance score01 (better)
Health score2 (better)0
Dividend score00
Valuation
P/S2.6× (better)202×
P/B4.1×–
FCF yield−73.9%−2.3% (better)
Fair value$6.61–
Margin of safety70.8%–
Growth
Revenue growth (TTM)−23.2%217% (better)
Profitability
Gross margin–−68.8%
Operating margin−210% (better)−696%
Net margin−257% (better)−584%
FCF margin−196% (better)−473%
Return on equity−1860%–
Financial health
Debt / equity0.01–
Interest coverage−276.1× (better)−307.0×
Current ratio1.44 (better)0.28
Altman Z-score−15.85 (better)−102.25
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.6%10.2%
Held by insiders59.3%6.9%
Insider net buying, 12 months–$4.1M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.